Bayer (BAYN) Given a €123.00 Price Target by Baader Bank Analysts

Baader Bank set a €123.00 ($143.02) price target on Bayer (FRA:BAYN) in a report published on Monday, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.

Other equities analysts also recently issued research reports about the stock. Kepler Capital Markets set a €70.00 ($81.40) price target on shares of Bayer and gave the stock a neutral rating in a report on Monday, March 25th. JPMorgan Chase & Co. set a €70.00 ($81.40) price target on shares of Bayer and gave the stock a neutral rating in a report on Thursday, March 28th. UBS Group set a €110.00 ($127.91) price target on shares of Bayer and gave the stock a buy rating in a report on Thursday, March 28th. Deutsche Bank set a €70.00 ($81.40) price objective on shares of Bayer and gave the stock a neutral rating in a research note on Monday, April 1st. Finally, DZ Bank reaffirmed a neutral rating on shares of Bayer in a research note on Tuesday, April 2nd. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have assigned a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of €81.72 ($95.02).

Shares of FRA:BAYN opened at €61.65 ($71.69) on Monday. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Read More: Do stock splits help investors?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.